Table 1.
Value | |
---|---|
Demographics | |
Age, yr, mean ± SD | 50 ± 15 |
Sex, F, n (%) | 35 (70) |
BMI, kg m−1, mean ± SD | 26 ± 5 |
Comorbidities, n (%) | |
Asthma | 12 (24) |
CAD | 4 (8) |
COPD | 2 (4) |
Diabetes mellitus | 2 (4) |
Hypertension | 14 (28) |
ILD | 2 (4) |
Smoking status, n (%) | |
Former | 10 (2) |
Never | 40 (80) |
Medications, n (%) | |
ACE inhibitor/ARB | 8 (16) |
BB | 5 (10) |
CCB | 1 (2) |
COVID-19 clinical characteristics | |
Time from diagnosis to CPET, mean ± SD, mo | 6 ± 4 |
Hospital admission, n (%) | 5 (10) |
ICU admission, n (%) | 3 (6) |
Mechanical ventilation, n (%) | 3 (6) |
Post–COVID-19 symptoms, n (%) | |
Two or more of the following | 6 (12) |
Dyspnea on exertion | 28 (56) |
Decreased endurance | 13 (26) |
Chest pain | 3 (6) |
Testing results | |
CT chest, n (%) | 41 (82) |
Time from CT chest to CPET, mean ± SD, mo | 1 ± 2 |
Normal findings, n (%) | 14 (34) |
Minimal GGO, n (%) | 10 (24) |
Bronchial wall thickening, n (%) | 13 (32) |
Peripheral reticulation, n (%) | 1 (2) |
Pulmonary function test, n (%) | 50 (100) |
Time from PFT to CPET, mean ± SD, mo | 1 ± 2 |
FVC, L; FVC % predicted, mean ± SD | 3.8 ± 1; 96 ± 14 |
FEV1, L; FEV1% predicted, mean ± SD | 3.1 ± 0.9; 98 ± 13 |
FEV1/FVC, %, mean ± SD | 95 ± 12 |
TLC, L; TLC % predicted, mean ± SD | 5.9 ± 1.3; 103 ± 13* |
RVol, L; RVol % predicted, mean ± SD | 2.2 ± 0.6; 108 ± 21* |
DlCOcor mL min-1 mm Hg; DlCOcor % predicted, mean ± SD | 26 ± 8; 109 ± 22† |
Echocardiography at rest, n (%) | 39 (78) |
Time from echocardiogram to CPET, mean ± SD, mo | 2 ± 3 |
Normal LV ejection fraction, n (%) | 39 (100) |
Grade 1 RV diastolic dysfunction, n (%) | 2 (5) |
RV systolic dysfunction, n (%) | 8 (21) |
RVSP, mean ± SD, mm Hg | 38 ± 3 |
MPS at rest, n (%) | 8 (16) |
Time from CPET to MPS, mean ± SD, d | 10 ± 90 |
Normal, n (%) | 8 (100) |
C-MRI at rest, n (%) | 9 (18) |
Time from CPET to C-MRI, mean ± SD, mo | 1 ± 3 |
CPET | |
Reason for discontinuation of CPET, n (%) | |
Dyspnea | 20 (40) |
Overall fatigue | 15 (30) |
Leg fatigue | 11 (22) |
Lightheadedness | 2 (4) |
Chest pain | 2 (4) |
Dyspnea, Borg score, mean ± SD | 8 ± 1 |
Leg fatigue, Borg score, mean ± SD | 8 ± 2 |
WR max, Watts; % predicted, mean ± SD | 144 ± 49; 95 ± 22 |
o2 max, L min−1; % predicted, mean ± SD | 1.6 ± 0.4; 95 ± 28 |
o2 max/BW, ml kg min−1; % predicted, mean ± SD | 22.2 ± 6.0; 94 ± 29 |
co2 max, L min−1; % predicted, mean ± SD | 2.0 ± 0.5; 95 ± 26 |
RER, mean ± SD | 1.2 ± 0.1 |
e max, L min−1, mean ± SD | 77 ± 19 |
Vd/Vt, mean ± SD | 0.2 ± 0.1 |
HR max, beats min−1, mean ± SD | 155 ± 22 |
HRR, beats min−1, mean ± SD | 16 ± 14 |
SpO2, % mean ± SD | 94 ± 4 |
Lactate at peak, mmol L−1, mean ± SD | 10 ± 3‡ |
Anaerobic threshold, %, mean ± SD | 51 ± 16 |
Oxygen pulse, ml beat; % predicted, mean ± SD | 11 ± 3.8; 99 ± 33 |
SBP; DBP, mm Hg, mean ± SD | 169 ± 25; 81 ± 13 |
Definition of abbreviations: ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BB = β-adrenergic receptor antagonist; BMI = body mass index; CAD = coronary artery disease; COVID-19 = coronavirus disease; CCB = calcium channel blocker; C-MRI = cardiac magnetic resonance imaging; COPD = chronic obstructive pulmonary disease; CPET = cardiopulmonary exercise testing; CT = computed tomography; DBP = diastolic blood pressure; DlCOcor = DlCO corrected for altitude; GGO = ground glass opacifications; HR max = maximum heart rate; HRR = heart rate reserve; ILD = interstitial lung disease; LV = left ventricle; MPS = myocardial perfusion scan; PFT = pulmonary function test; RER = respiratory exchange ratio; RVol = residual volume; RV = right ventricle; RVSP = right ventricular systolic pressure; SBP = systolic blood pressure; SpO2 = oxygen saturation as measured by pulse oximetry; Vco2 max = exhaled maximum co2; o2 max = maximum o2; o2 max/BW = maximum Vo2 per kilogram body weight; WR max = maximum work rate.
N = 50.
n = 38.
n = 41.
n = 39.